首页> Clinical lymphoma, myeloma & leukemia> Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.

Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL Registry.

导出 OA

翻译打印收藏纠错

第一作者： Anthony R,Mato

第一单位： Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: matoa@mskcc.org.

作者： Anthony R,Mato ^[1] ; Jacqueline C,Barrientos ^[2] ; Nilanjan,Ghosh ^[3] ; John M,Pagel ^[4] ; Danielle M,Brander ^[5] ; Meghan,Gutierrez ^[6] ; Karen,Kadish ^[7] ; Brian,Tomlinson ^[8] ; Reethi,Iyengar ^[9] ; David,Ipe ^[9] ; Sandhya,Upasani ^[9] ; Carlos I,Amaya-Chanaga ^[9] ; Murali,Sundaram ^[10] ; Jennifer,Han ^[10] ; Nick,Giafis ^[9] ; Jeff P,Sharman ^[11]

作者单位： Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: matoa@mskcc.org. ^[1] Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY. ^[2] Levine Cancer Institute, Atrium Health, Charlotte, NC. ^[3] Swedish Cancer Institute Hematologic Malignancies Program, Seattle, WA. ^[4] Duke University Health System, Durham, NC. ^[5] Lymphoma Research Foundation, New York, NY. ^[6] Tufts Medical Center, Boston, MA. ^[7] CancerCare, New York, NY. ^[8] Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA. ^[9] Janssen Scientific Affairs, LLC, Horsham, PA. ^[10] Willamette Valley Cancer Institute & Research Center/US Oncology Research, Eugene, OR. ^[11]

关键词 Chemoimmunotherapy Ibrutinib Novel agents Prognostic marker Real-world registry